Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
GLYR1 Biologics Sequence Review Report 2026: Cytokine-like nuclear factor N-PAC Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GLYR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GIG44 Biologics Sequence Review Report 2026: Putative insulin-like growth factor 2-associated protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GIG44 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GHSR Biologics Sequence Review Report 2026: Growth hormone secretagogue receptor type 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GHSR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GAGE12J Biologics Sequence Review Report 2026: G antigen 12J Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GAGE12J sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FP248 Biologics Sequence Review Report 2026: Putative chemokine-related protein FP248 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FP248 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FOSL2 Biologics Sequence Review Report 2026: Fos-related antigen 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FOSL2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FOSL1 Biologics Sequence Review Report 2026: Fos-related antigen 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FOSL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FIBP Biologics Sequence Review Report 2026: Acidic fibroblast growth factor intracellular-binding protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FIBP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FFAR4 Biologics Sequence Review Report 2026: Free fatty acid receptor 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FFAR4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
F11R Biologics Sequence Review Report 2026: Junctional adhesion molecule A Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of F11R sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ETAA1 Biologics Sequence Review Report 2026: Ewing's tumor-associated antigen 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ETAA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ESRRB Biologics Sequence Review Report 2026: Steroid hormone receptor ERR2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ESRRB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.